These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 11158747)
1. Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. Polk RE; Brophy DF; Israel DS; Patron R; Sadler BM; Chittick GE; Symonds WT; Lou Y; Kristoff D; Stein DS Antimicrob Agents Chemother; 2001 Feb; 45(2):502-8. PubMed ID: 11158747 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. Brophy DF; Israel DS; Pastor A; Gillotin C; Chittick GE; Symonds WT; Lou Y; Sadler BM; Polk RE Antimicrob Agents Chemother; 2000 Apr; 44(4):978-84. PubMed ID: 10722500 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. Polk RE; Crouch MA; Israel DS; Pastor A; Sadler BM; Chittick GE; Symonds WT; Gouldin W; Lou Y Pharmacotherapy; 1999 Dec; 19(12):1378-84. PubMed ID: 10600086 [TBL] [Abstract][Full Text] [Related]
4. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Cato A; Cavanaugh J; Shi H; Hsu A; Leonard J; Granneman R Clin Pharmacol Ther; 1998 Apr; 63(4):414-21. PubMed ID: 9585795 [TBL] [Abstract][Full Text] [Related]
5. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Barditch-Crovo P; Trapnell CB; Ette E; Zacur HA; Coresh J; Rocco LE; Hendrix CW; Flexner C Clin Pharmacol Ther; 1999 Apr; 65(4):428-38. PubMed ID: 10223781 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir. Tran JQ; Petersen C; Garrett M; Hee B; Kerr BM Clin Pharmacol Ther; 2002 Dec; 72(6):615-26. PubMed ID: 12496743 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Borin MT; Chambers JH; Carel BJ; Gagnon S; Freimuth WW Clin Pharmacol Ther; 1997 May; 61(5):544-53. PubMed ID: 9164416 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects. McRae M; Clay PG; Anderson PL; Glaros AG Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947 [TBL] [Abstract][Full Text] [Related]
9. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE; HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619 [TBL] [Abstract][Full Text] [Related]
10. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. Gallicano K; Khaliq Y; Carignan G; Tseng A; Walmsley S; Cameron DW Clin Pharmacol Ther; 2001 Aug; 70(2):149-58. PubMed ID: 11503009 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects. Ford SL; Chen YC; Lou Y; Borland J; Min SS; Yuen GJ; Shelton MJ Antimicrob Agents Chemother; 2008 Feb; 52(2):534-8. PubMed ID: 18056271 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects. Cao YJ; Smith PF; Wire MB; Lou Y; Lancaster CT; Causon RC; Bigelow GE; Martinez E; Fuchs EJ; Radebaugh C; McCabe S; Hendrix CW Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901 [TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. Paine MF; Wagner DA; Hoffmaster KA; Watkins PB Clin Pharmacol Ther; 2002 Nov; 72(5):524-35. PubMed ID: 12426516 [TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection. Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA; Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762 [TBL] [Abstract][Full Text] [Related]
16. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. Seminari E; De Bona A; Gentilini G; Galli L; Schira G; Gianotti N; Uberti-Foppa C; Soldarini A; Dorigatti F; Lazzarin A; Castagna A J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects. Hendrix CW; Wakeford J; Wire MB; Lou Y; Bigelow GE; Martinez E; Christopher J; Fuchs EJ; Snidow JW Pharmacotherapy; 2004 Sep; 24(9):1110-21. PubMed ID: 15460171 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir. Sadler BM; Gillotin C; Lou Y; Eron JJ; Lang W; Haubrich R; Stein DS Antimicrob Agents Chemother; 2001 Dec; 45(12):3663-8. PubMed ID: 11709366 [TBL] [Abstract][Full Text] [Related]
19. Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects. Vourvahis M; Davis J; Wang R; Layton G; Choo HW; Chong CL; Tawadrous M Antimicrob Agents Chemother; 2012 Aug; 56(8):4303-9. PubMed ID: 22644026 [TBL] [Abstract][Full Text] [Related]